New Hampshire to offer Gardasil vaccinations free to all girls

Share this article:
New Hampshire health officials plan to offer Merck’s Gardasil human papillomavirus (HPV) vaccine free to all girls to help protect them against cervical cancer. “New Hampshire will be the first state in the country to offer the vaccine in its universal children’s (vaccine) program,” New Hampshire Health and Human Services Commissioner John Stephen told the Associated Press. The New Hampshire Vaccines for Children program is funded by the federal government and private insurers and offers “no-cost” immunizations to children through age 18. The program also pays to vaccinate children against other diseases, such as hepatits A and B, polio and measles. $4.8 million has been budgeted for the vaccine next year, reports said. New Hampshire officials said doctors can begin ordering the vaccine Friday, for shipment in January. State officials hope 17,000 young women -- 25% of those eligible --will come forward for the vaccinations during 2007. Gardasil was approved by the FDA in June for females 9 to 26 years old. The vaccine helps protect against four types of HPV responsible for most strains of the disease. A Centers for Disease Control panel recommended Gardasil for use in girls 11 and 12, and down to 9 per a physician’s discretion, and for all those not vaccinated from 13 to 26.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...